ARC Desk

Antibiotic Resistance Market Size will Grow at 5.5% to a Record $12.11 Bn by 2026

Lehdistötiedote   •   Syys 17, 2019 09:41 EEST

The global Antibiotic Resistance Market is anticipated to grow at 5.5 % CAGR during the forecast period 2018 to 2026 and reach around US$ 12.11 Billion by 2026.

The Antibiotic Resistance Market report provides a holistic view of the industry along with the factors that are driving and restraining the growth of the global Antibiotic Resistance Market. In addition, the report provides a qualitative and quantitative data that helps in understanding of the historic, current and future industry scenario. The report provides the detailed analysis of the segment and the factors driving the growth of the segment.

The report provides the value chain analysis, Porters Five analysis, and cost structure analysis that gives an industry outlook. It also provides overview of manufacturing plant of the major companies that covers the location of the manufacturing unit, R&D capacity and supplier of the raw materials.

Download Free Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/933

Scope of the Antibiotic Resistance Market Report:

The study provides a decisive view of the Antibiotic Resistance Market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Market Segmentation:

Market By Disease

  • Complicated Urinary Tract Infection (cUTI)
  • Complicated Intra-Abdominal Infections (cIAI)
  • Blood Stream Infections (BSI)
  • Clostridium difficile infections (CDI)
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Community Acquired Bacterial Pneumonia (CABP)

Market By Pathogen

  • Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
  • Pseudomonas aeruginosa (Carbapenem-Resistant)
  • Staphylococcus Aureus (Methicillin-Resistant)
  • E. coli/K. pneumoniae (Carbapenem-Resistant)
  • Streptococcus pneumoniae (Penicillin-Non-Susceptible)
  • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
  • Enterococcus faecium (Vancomycin-Resistant)
  • Haemophilus Influenzae (Ampicillin-Resistant)

Market By Drug Class

  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Cephalosporins
  • Combination therapies
  • Others

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

The market research study on “Antibiotic Resistance Market (By Disease - cUTI, cIAI, BSI, CDI, ABSSSI, HABP/VABP, CABP; By Pathogen - Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, E. coli/K. Pneumoniae, Streptococcus Pneumoniae, Clostridium difficile, Enterococcus faecium, Haemophilus Influenzae; By Drug Class - Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination therapies, Others) - Global Industry Size, Share, Trends and Forecast 2018 - 2026” offers a detailed insights on Global antibiotic resistance market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report provides insights on global antibiotic resistance market by disease type, pathogen, drug class and major geographic regions. The report also covers basic healthcare development policies. Secondly, the report covers global antibiotic resistance market size and segment markets by disease type, pathogen, drug class and geography along with the information on companies operating in the market. 

The global Antibiotic Resistance Market report cover the comprehensive mapping of the industry players that are operating in target market along with the player positioning based on their business strengths and product offerings which provides the competitive outlook of the industry.

The major players in the Global Antibiotic Resistance Market include:-

TPfizer, Merck, Allergan, The Medicines Company, Melinta Therapeutics, Phage Technologies S.A, Tetraphase Pharmaceuticals, Nabriva Therapeutics. Macrolide Pharmaceuticals, Nemesis Bioscience, Westway Health, AmpliPhi Biosciences and BioVersys GmbH.

The report provides the business outlook of the major player with their business overview, product portfolio, revenue by segment and region. It covers a detailed analysis in the key strategies adopted by the players in order to gain a business upfront against other competitors. The report also provides the strategic overview covering the activities of business players such as merger and acquisition, partnerships and agreements that gives an understanding of their current business scenario.

Key Questions Answered in the Report

The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-

  • What is the overall structure of the market?
  • What was the historical value and what is the forecasted value of the market?
  • What are the key product level trends in the market?
  • What are the market level trends in the market?
  • Which of the market players are leading and what are their key differential strategies to retain their stronghold?
  • Which are the most lucrative regions in the market space?

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope

1.1.1. Definition of Antibiotic Resistance

1.1.2. Market Segmentation

1.1.3. List of Abbreviations

1.2. Summary

1.2.1. Market Snapshot

1.2.2. Antibiotic Resistance Market By Disease

1.2.2.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison By Disease (2015-2026)

1.2.2.2. Global Antibiotic Resistance Market Revenue Share By Disease in 2017

1.2.2.3. Complicated Urinary Tract Infection (cUTI)

1.2.2.4. Complicated Intra-Abdominal Infections (cIAI)

1.2.2.5. Blood Stream Infections (BSI)

1.2.2.6. Clostridium difficile infections (CDI)

1.2.2.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

1.2.2.8. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)

1.2.2.9. Community Acquired Bacterial Pneumonia (CABP)

1.2.2.10. Others

1.2.3. Antibiotic Resistance Market By Pathogen

1.2.3.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison By Pathogen (2015-2026)

1.2.3.2. Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)

1.2.3.3. Pseudomonas aeruginosa (Carbapenem-Resistant)

1.2.3.4. Staphylococcus Aureus (Methicillin-Resistant)

1.2.3.5. E. coli/K. pneumoniae (Carbapenem-Resistant)

1.2.3.6. Streptococcus pneumoniae (Penicillin-Non-Susceptible)

1.2.3.7. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

1.2.3.8. Enterococcus faecium (Vancomycin-Resistant)

1.2.3.9. Haemophilus Influenzae (Ampicillin-Resistant)

1.2.3.10. Others

1.2.4. Antibiotic Resistance Market By Drug Class

1.2.4.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)

1.2.4.3. Lipoglycopeptides

1.2.4.4. Tetracyclines

1.2.4.5. Cephalosporins

1.2.4.6. Combination therapies

1.2.4.7. Others

1.2.5. Antibiotic Resistance Market by Geography

1.2.5.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison by Geography (2015-2026)

1.2.5.2. North America Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)

1.2.5.3. Europe Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)

1.2.5.4. Asia-Pacific Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)

1.2.5.5. Latin America Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)

1.2.5.6. Middle East and Africa (MEA) Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers

2.2. Restraints and Challenges

2.3. Growth Opportunities

2.4. Porter’s Five Forces Analysis

2.4.1. Bargaining Power of Suppliers

2.4.2. Bargaining Power of Buyers

2.4.3. Threat of Substitute

2.4.4. Threat of New Entrants

2.4.5. Degree of Competition

2.5. Value Chain Analysis

2.6. Cost Structure Analysis

2.6.1. Raw Material and Suppliers

2.6.2. Manufacturing Process Analysis

2.7. Regulatory Compliance

2.8. Competitive Landscape, 2017

2.8.1. Player Positioning Analysis

2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Lipoglycopeptides Production Date of Global Antibiotic Resistance Major Manufacturers in 2017

3.2. Manufacturing Plants Distribution of Global Antibiotic Resistance Major Manufacturers in 2017

3.3. R&D Status and Technology Source of Global Antibiotic Resistance Major Manufacturers in 2017

3.4. Raw Materials Sources Analysis of Global Antibiotic Resistance Major Manufacturers in 2017

CHAPTER 4. ANTIBIOTIC RESISTANCE MARKET BY DISEASE

4.1. Global Antibiotic Resistance Revenue By Disease

4.2. Complicated Urinary Tract Infection (cUTI)

4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

4.3. Complicated Intra-Abdominal Infections (cIAI)

4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

4.4. Blood Stream Infections (BSI)

4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

4.5. Clostridium difficile infections (CDI)

4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

4.6. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

4.7. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)

4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

4.8. Community Acquired Bacterial Pneumonia (CABP)

4.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

4.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

4.9. Other

4.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

4.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. ANTIBIOTIC RESISTANCE MARKET BY PATHOGEN

5.1. Global Antibiotic Resistance Revenue By Pathogen

5.2. Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)

5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

5.3. Pseudomonas aeruginosa (Carbapenem-Resistant)

5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

5.4. Staphylococcus Aureus (Methicillin-Resistant)

5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

5.5. E. coli/K. pneumoniae (Carbapenem-Resistant)

5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

5.6. Streptococcus pneumoniae (Penicillin-Non-Susceptible)

5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

5.7. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

5.8. Enterococcus faecium (Vancomycin-Resistant)

5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

5.9. Haemophilus Influenzae (Ampicillin-Resistant)

5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

5.10. Others

5.10.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

5.10.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. ANTIBIOTIC RESISTANCE MARKET BY DRUG CLASS

6.1. Global Antibiotic Resistance Revenue By Drug Class

6.2. Oxazolidinones

6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

6.3. Lipoglycopeptides

6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

6.4. Tetracyclines

6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

6.5. Cephalosporins

6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

6.6. Combination therapies

6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

6.7. Others

6.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)

6.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

7.1. North America Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)

7.2. North America Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)

7.3. U.S.

7.3.1. U.S. Antibiotic Resistance Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

7.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

7.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

7.4. Canada

7.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

7.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

7.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

7.5. Mexico

7.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

7.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

7.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

8.1. Europe Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)

8.2. Europe Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)

8.3. UK

8.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

8.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

8.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

8.4. Germany

8.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

8.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

8.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

8.5. France

8.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

8.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

8.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

8.6. Spain

8.6.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

8.6.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

8.6.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

8.7. Rest of Europe

8.7.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

8.7.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

8.7.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

9.1. Asia-Pacific Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)

9.2. Asia-Pacific Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)

9.3. China

9.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

9.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

9.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

9.4. Japan

9.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

9.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

9.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

9.5. India

9.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

9.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

9.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

9.6. Australia

9.6.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

9.6.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

9.6.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

9.7. South Korea

9.7.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

9.7.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

9.7.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

9.8. Rest of Asia-Pacific

9.8.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

9.8.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

9.8.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

10.1. Latin America Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)

10.2. Latin America Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)

10.3. Brazil

10.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

10.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

10.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

10.4. Argentina

10.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

10.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

10.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

10.5. Rest of Latin America

10.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

10.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

10.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

11.1. Middle East Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)

11.2. Middle East Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)

11.3. Saudi Arabia

11.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

11.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

11.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

11.4. UAE

11.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

11.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

11.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

11.5. Rest of Middle East

11.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

11.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

11.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA ANTIBIOTIC RESISTANCE MARKET BY COUNTRY

12.1. Africa Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)

12.2. Africa Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)

12.3. South Africa

12.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

12.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

12.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

12.4. Egypt

12.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

12.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

12.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

12.5. Rest of Africa

12.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)

12.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)

12.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. TPfizer

13.1.1. Company Snapshot

13.1.2. Overview

13.1.3. Financial Overview

13.1.4. Type Portfolio

13.1.5. Key Developments

13.1.6. Strategies

13.2. Merck

13.2.1. Company Snapshot

13.2.2. Overview

13.2.3. Financial Overview

13.2.4. Type Portfolio

13.2.5. Key Developments

13.2.6. Strategies

13.3. Allergan

13.3.1. Company Snapshot

13.3.2. Overview

13.3.3. Financial Overview

13.3.4. Type Portfolio

13.3.5. Key Developments

13.3.6. Strategies

13.4. The Medicines Company

13.4.1. Company Snapshot

13.4.2. Overview

13.4.3. Financial Overview

13.4.4. Type Portfolio

13.4.5. Key Developments

13.4.6. Strategies

13.5. Melinta Therapeutics

13.5.1. Company Snapshot

13.5.2. Overview

13.5.3. Financial Overview

13.5.4. Type Portfolio

13.5.5. Key Developments

13.5.6. Strategies

13.6. Phage Technologies S.A

13.6.1. Company Snapshot

13.6.2. Overview

13.6.3. Financial Overview

13.6.4. Type Portfolio

13.6.5. Key Developments

13.6.6. Strategies

13.7. Tetraphase Pharmaceuticals

13.7.1. Company Snapshot

13.7.2. Overview

13.7.3. Financial Overview

13.7.4. Type Portfolio

13.7.5. Key Developments

13.7.6. Strategies

13.8. Nabriva Therapeutics

13.8.1. Company Snapshot

13.8.2. Overview

13.8.3. Financial Overview

13.8.4. Type Portfolio

13.8.5. Key Developments

13.8.6. Strategies

13.9. Macrolide Pharmaceuticals

13.9.1. Company Snapshot

13.9.2. Overview

13.9.3. Financial Overview

13.9.4. Type Portfolio

13.9.5. Key Developments

13.9.6. Strategies

13.10. Nemesis Bioscience

13.10.1. Company Snapshot

13.10.2. Overview

13.10.3. Financial Overview

13.10.4. Type Portfolio

13.10.5. Key Developments

13.10.6. Strategies

13.11. Westway Health

13.11.1. Company Snapshot

13.11.2. Overview

13.11.3. Financial Overview

13.11.4. Type Portfolio

13.11.5. Key Developments

13.11.6. Strategies

13.12. AmpliPhi Biosciences

13.12.1. Company Snapshot

13.12.2. Overview

13.12.3. Financial Overview

13.12.4. Type Portfolio

13.12.5. Key Developments

13.12.6. Strategies

13.13. BioVersys GmbH

13.13.1. Company Snapshot

13.13.2. Overview

13.13.3. Financial Overview

13.13.4. Type Portfolio

13.13.5. Key Developments

13.13.6. Strategies

13.14. Others

13.14.1. Company Snapshot

13.14.2. Overview

13.14.3. Financial Overview

13.14.4. Type Portfolio

13.14.5. Key Developments

13.14.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology

14.1.1. Initial Data Search

14.1.2. Secondary Research

14.1.3. Primary Research

14.2. Assumptions and Scope

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/933

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.